PATENT CLAIM ANALYSIS

Application Number: 16224450
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "158100"]

Abstract:
This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer.

Claim (Index 203):
The method of suppressing of  claim 202 , wherein the TACR3 inhibitor is selected from the group consisting of osanetant, SB 222200, and talnetant.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 98.0
- Lexical Diversity: 1.87302
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15007002', '11698291', '14289712', '13639864', '13806929']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7877377283520011
- 35 USC 102 Novelty (BERT): 0.5188362733851479
- Combined Prediction Score: 0.7608475828553158
- Mean Citation Score: 279.291308
- Max Citation Score: 297.03824
- Similarity Product: 190.5696468104172

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test